Evidence map›Paper›PMID 33829389›Full record

ReviewHeart failure reviews2022

Speckle tracking echocardiography in primary mitral regurgitation: should we reconsider the time for intervention?

Maria Concetta Pastore, Giulia Elena Mandoli, Aleksander Dokollari, Gianluigi Bisleri, Flavio D'Ascenzi, Ciro Santoro, Marcelo Haertel Miglioranza, Marta Focardi, Luna Cavigli, Giuseppe Patti and 3 more

Open access · hybridAbstract readReview
In one paragraph

Review in Heart failure reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 23 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 4 countries.

Maria Concetta Pastore *Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Viale Bracci 16, Siena, Italy. pastore2411@gmail.com.ORCID 0000-0002-7223-141X
Giulia Elena Mandoli *Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Viale Bracci 16, Siena, Italy.ORCID 0000-0002-3184-3006
Aleksander DokollariDivision of Cardiac Surgery, University of Toronto, Toronto, ON, Canada.
Gianluigi BisleriDivision of Cardiac Surgery, University of Toronto, Toronto, ON, Canada.
Flavio D'AscenziDepartment of Medical Biotechnologies, Division of Cardiology, University of Siena, Viale Bracci 16, Siena, Italy.
Ciro SantoroDepartment of Advanced Biomedical Science, Federico II University Hospital Naples, Naples, Italy.
Marcelo Haertel MiglioranzaCardiology Institute of Rio Grande Do Sul, Porto Alegre, Brazil.
Marta FocardiDepartment of Medical Biotechnologies, Division of Cardiology, University of Siena, Viale Bracci 16, Siena, Italy.
Luna CavigliDepartment of Medical Biotechnologies, Division of Cardiology, University of Siena, Viale Bracci 16, Siena, Italy.
Giuseppe PattiMaggiore Della Carità Hospital, University of Eastern Piedmont, Novara, Italy.
Serafina ValenteDepartment of Medical Biotechnologies, Division of Cardiology, University of Siena, Viale Bracci 16, Siena, Italy.
Sergio MondilloDepartment of Medical Biotechnologies, Division of Cardiology, University of Siena, Viale Bracci 16, Siena, Italy.
Matteo CameliDepartment of Medical Biotechnologies, Division of Cardiology, University of Siena, Viale Bracci 16, Siena, Italy.ORCID 0000-0003-3872-8964
University of Siena · ITUniversity of Toronto · CAFederico II University Hospital · ITInstituto do Cérebro · BRUniversità degli Studi del Piemonte Orientale “Amedeo Avogadro” · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Thanks to the improvement in mitral regurgitation (MR) diagnostic and therapeutic management, with the introduction of minimally invasive techniques which have considerably reduced the individual surgical risk, the optimization of the timing for MR "open" or percutaneous surgical treatment has become a main concern which has highly raised scientific interest. In fact, the current indications for intervention in MR, especially in asymptomatic patients, rely on echocardiographic criteria with high severity cut-offs that are fulfilled only when not only mitral valve apparatus but also the cardiac chambers' structure and function are severely impaired, which results in poor benefits for post-operative clinical outcome. This led to the need of new indices to redefine the optimal surgical timing in these patients. Speckle tracking echocardiography provides early markers of cardiac dysfunction due to subtle myocardial impairment; therefore, it could offer pivotal information in this setting. In fact, left ventricular and left atrial strains have already shown evidence about their usefulness in recognizing MR impact not only on symptoms and quality of life but also on cardiovascular events and new-onset atrial fibrillation in these patients. Moreover, right ventricular strain could be used to identify those patients with advanced cardiac damage and different grades of right ventricular dysfunction, which entails higher risks for cardiac surgery that could overweigh surgical benefits. This review aims to describe the importance of reconsidering the timing of intervention in MR and to analyze the potential additive value of speckle tracking echocardiography in this clinical setting.

Indexed as

Mitral Valve InsufficiencyVentricular Dysfunction, RightEchocardiographyHeart VentriclesHumansQuality of LifeEchocardiographyMitral regurgitationSpeckle trackingSurgeryTimingTreatment

Identifiers

PMID33829389
PMCPMC9197800
OpenAlexW3149998952

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.